BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32363992)

  • 1. Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report.
    Iijima Y; Sakakibara R; Ishizuka M; Honda T; Shirai T; Okamoto T; Tateishi T; Sakashita H; Tamaoka M; Takemoto A; Kumaki Y; Ikeda S; Miyazaki Y
    Immunotherapy; 2020 Jun; 12(8):563-569. PubMed ID: 32363992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
    Takada K; Sugita S; Murase K; Kikuchi T; Oomori G; Ito R; Hayasaka N; Miyanishi K; Iyama S; Ikeda H; Kobune M; Emori M; Kato J; Hasegawa T
    Thorac Cancer; 2019 Dec; 10(12):2312-2315. PubMed ID: 31617320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma.
    Kawachi H; Kunimasa K; Kukita Y; Nakamura H; Honma K; Kawamura T; Inoue T; Tamiya M; Kuhara H; Nishino K; Mizote Y; Akazawa T; Tahara H; Kumagai T
    Immunotherapy; 2021 Jul; 13(10):799-806. PubMed ID: 34030451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab.
    Lin YT; Li CF; Wu HC; Jan YH; Kuo YH
    Front Immunol; 2023; 14():1131448. PubMed ID: 37051241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Shinno Y; Yoshida A; Masuda K; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Yamamoto N; Yatabe Y; Ohe Y
    Clin Lung Cancer; 2022 Jul; 23(5):386-392. PubMed ID: 35618627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients.
    Crombé A; Alberti N; Villard N; Pilleul F; Buy X; Le Loarer F; Kind M
    Eur Radiol; 2019 Sep; 29(9):4730-4741. PubMed ID: 30762113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors.
    Matsushita M; Kuwamoto S
    Acta Cytol; 2018; 62(5-6):456-462. PubMed ID: 30286456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thorahcic SMARCA4-deficient undifferentiated tumors with ganglioneuroma and enchondroma: implications for SLC7A11 and ARID1A expression: a case report.
    Kito Y; Kawashima K; Saigo C; Hasegawa M; Nomura S; Mikamo T; Hanamatsu Y; Matsuo Y; Takeuchi T
    Diagn Pathol; 2022 Feb; 17(1):29. PubMed ID: 35151345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytology of SMARCA4-Deficient Thoracic Neoplasms: Comparative Analysis of SMARCA4-Deficient Non-Small Cell Lung Carcinomas and SMARCA4-Deficient Thoracic Sarcomas.
    Nambirajan A; Dutta R; Malik PS; Bubendorf L; Jain D
    Acta Cytol; 2021; 65(1):67-74. PubMed ID: 32854100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma.
    Khanchel F; Hedhili R; Zenaidi H; Helal I; Yahmadi A; Ben Néji H; Ksontini F; Ben Brahim E; Jouini R; Chadli A
    Gen Thorac Cardiovasc Surg; 2021 Jul; 69(7):1155-1158. PubMed ID: 33866513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Review of Literature.
    Stewart BD; Kaye F; Machuca T; Mehta HJ; Mohammed TL; Newsom KJ; Starostik P
    Int J Surg Pathol; 2020 Feb; 28(1):102-108. PubMed ID: 31382829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytopathological Features of
    Takeda M; Tani Y; Saijo N; Shimizu S; Taniguchi Y; Otsuka K; Nakao K; Tamiya A; Okishio K; Atagi S; Ohbayashi C; Kasai T
    Int J Surg Pathol; 2020 Feb; 28(1):109-114. PubMed ID: 31448657
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.
    Gantzer J; Davidson G; Vokshi B; Weingertner N; Bougoüin A; Moreira M; Lindner V; Lacroix G; Mascaux C; Chenard MP; Bertucci F; Davidson I; Kurtz JE; Sautès-Fridman C; Fridman WH; Malouf GG
    Oncologist; 2022 Jun; 27(6):501-511. PubMed ID: 35278076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources.
    Kuwamoto S; Matsushita M; Takeda K; Tanaka N; Endo Y; Yamasaki A; Kohashi K; Oda Y; Horie Y
    Hum Pathol; 2017 Dec; 70():92-97. PubMed ID: 28601660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Thoracic
    Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
    Kunimasa K; Nakamura H; Sakai K; Tamiya M; Kimura M; Inoue T; Nishino K; Kuhara H; Nakatsuka SI; Nishio K; Imamura F; Kumagai T
    Lung Cancer; 2019 Jun; 132():59-64. PubMed ID: 31097095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.
    Henon C; Blay JY; Massard C; Mir O; Bahleda R; Dumont S; Postel-Vinay S; Adam J; Soria JC; Le Cesne A
    Ann Oncol; 2019 Aug; 30(8):1401-1403. PubMed ID: 31114851
    [No Abstract]   [Full Text] [Related]  

  • 20. Innocuous clinical presentation of a SMARCA4-deficient thoracic sarcoma arising in a patient with chronic empyema thoracis.
    Nambirajan A; Parshad R; Goyal A; N K M; Jain D
    Pathology; 2019 Oct; 51(6):657-659. PubMed ID: 31470991
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.